Jie Wang
Zhiyong Ma
Dingzhi Huang
Yun Fan
Xinmin Yu
Sheng Hu
Ziping Wang
Zhihua Liu
Devrim Cabuk
Mahmut Gumus
Yiyuan Ma
Yan Wang
Yan Ma
Caicun Zhou
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
Department of Thoracic Medical Oncology, Lung Cancer Diagnosis and Treatment Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin/CN
Breast Cancer Center, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Hubei Cancer Hospital, Wuhan, China
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China
Jiangsu Cancer Hospital, Nanjing, China
Faculty of Medicine, Department of Medical Oncology, Erciyes University, Kayseri, Turkey
Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
BeiGene (Beijing) Co., Ltd., Beijing, China
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
China
N/A
Oncology (ONC)
Non Small Cell Lung cancer
Programmed death-ligand 1
Tislelizumab
Docetaxel
N/A
Randomized
III
NCT03358875
N/A
N/A